Related Experiment Video
Updated: Jun 5, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
1.8K
Iron deficiency and heart failure with preserved ejection fraction
Tetyana M Ternushchak1, Marianna I Tovt-Korshynska1, Snizhana V Feysa1
1UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|December 11, 2024
Summary
Iron deficiency (ID) is common in heart failure with preserved ejection fraction (HFpEF), affecting 63% of patients. This comorbidity significantly reduces functional capacity and quality of life.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a complex condition with multiple comorbidities.
- Iron deficiency (ID) is increasingly recognized as a significant comorbidity in heart failure patients.
Purpose of the Study:
- To determine the prevalence of iron deficiency (ID) in patients diagnosed with HFpEF.
- To investigate the relationship between ID and functional capacity in HFpEF patients.
- To assess the impact of ID on the quality of life in individuals with HFpEF.
Main Methods:
- A cohort of 121 consecutive outpatients newly diagnosed with HFpEF were analyzed.
- Patients were evaluated for iron status using serum ferritin and transferrin saturation (TSAT).
- Functional capacity was assessed using the 6-minute walk test (6MWT), and quality of life was measured with the Minnesota Living with Heart Failure Questionnaire.
Main Results:
- Iron deficiency (ID) was prevalent in 63% of the HFpEF patients studied.
- Patients with ID exhibited more severe HF symptoms, higher NT-proBNP and hs CRP levels, and poorer diastolic function.
- HFpEF patients with ID demonstrated significantly reduced functional capacity and lower quality of life scores.
Conclusions:
- Iron deficiency (ID) is a highly prevalent comorbidity in patients with HFpEF.
- The presence of ID is strongly associated with impaired functional capacity and diminished quality of life in HFpEF.
- Addressing ID may be crucial for improving clinical outcomes in HFpEF management.
More Related Videos
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.4K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.4K
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:22Heart Failure Drugs: Diuretics
340
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
340
01:20Mitral Regurgitation I: Introduction
2
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
2
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:26Heart Failure Drugs: Inotropic Agents
517
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
517